Abstract Human serum heme-albumin (HSA-heme-Fe) displays reactivity and spectroscopic properties similar to those of heme proteins. Here, the nitrite reductase activity of ferrous HSA-heme-Fe [HSA-heme-Fe(II)] is reported. The value of the second-order rate constant for the reduction of NO
Introduction
Human serum albumin (HSA), the most abundant protein in plasma (reaching a blood concentration of about 7.0 9 10 -4 M), participates in heme scavenging; in turn, heme-Fe endows HSA with reactivity and spectroscopic properties similar to those of heme proteins (see [1] [2] [3] ). The occurrence of multiple conformations of human serum heme-albumin (HSA-heme-Fe) greatly influences its reactivity and ligand transportation properties. It should be noted that the ligation and the redox state of the heme Fe atom affect the ability of HSA-heme-Fe to interact with endogenous and exogenous ligands circulating in the bloodstream, and vice versa (see [3] ).
Although ferrous HSA-heme-Fe [HSA-heme-Fe(II)] is rapidly oxidized by O 2 , double and triple mutants of HSAheme-Fe(II), as well as monomeric, dimeric, trimeric, tetrameric, and octameric HSA-tetraphenylporphirinatoiron(II) complexes have been developed as blood substitutes (see [4, 5] ). Furthermore, HSA-heme-Fe(II) reversibly binds CO and NO, and its reactivity appears to be modulated in an allosteric fashion by several drugs, such as ibuprofen, warfarin, and abacavir [6] [7] [8] [9] [10] . Moreover, ferric HSA-heme-Fe [HSA-heme-Fe(III)] binds not only anionic and neutral ligands (e.g., azide, cyanide, fluoride, and imidazole) [11, 12] but also NO, leading to the reductive nitrosylation of the heme Fe atom, i.e., the formation of nitrosylated HSAheme-Fe(II) [HSA-heme-Fe(II)-NO] [13] . In addition, HSA-heme-Fe displays (pseudo)enzymatic properties; thus, HSA-heme-Fe(II)-NO reacts with O 2 , leading to nitrate [14] ; HSA-heme-Fe(II)-NO and HSA-heme-Fe(III) catalyze the isomerization of peroxynitrite to nitrate [15] [16] [17] [18] ; and HSA-heme-Fe(III) exhibits weak catalase and peroxidase activities [12, 19, 20] . Remarkably, the ligand-binding and (pseudo)enzymatic properties of HSA-heme-Fe are competitively inhibited and/or modulated by the binding of allosteric effectors, such as drugs, to fatty acid (FA) sites 2, 6, and 7 (FA2, FA6, and FA7, respectively) (see [1] [2] [3] 9] ).
Here, the nitrite reductase activity of HSA-heme-Fe(II) is reported and analyzed in parallel with that of heme proteins [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . Remarkably, the binding of warfarin to the FA2 site inhibits the nitrite reductase activity of HSAheme-Fe(II), highlighting the role of drugs in allosterically modulating HSA-heme-Fe reactivity.
Materials and methods
HSA (essentially FA-free), hemin (Fe(III)-protoporphyrin IX) chloride, and warfarin were obtained from SigmaAldrich (St. Louis, MO, USA). Sodium nitrite (NaNO 2 ) and sodium dithionite (Na 2 S 2 O 4 ) were obtained from Merck KGaA (Darmstadt, Germany). NO (from Aldrich Chemical Co., Milwaukee, WI, USA) was purified by flowing it through a NaOH column in order to remove acidic nitrogen oxides. All products were of analytical or reagent grade and were used without further purification.
HSA-heme-Fe(III) (final concentration 3.5 9 10 -6 M) was prepared by adding a 1.6-fold excess of HSA solution (5.0 9 10 -2 M sodium phosphate buffer, pH 6.5-8.2) to the heme-Fe(III) solution (1.0 9 10 -2 M NaOH) at 20°C. HSA-heme-Fe(II) (3.5 9 10 -6 M) was obtained, under anaerobic conditions, by adding sodium dithionite (final concentration 1.0 9 10 -3 to 5.0 9 10 -3 M). Remarkably, a sodium dithionite concentration of \1.0 9 10 -2 M does not effectively reduce NO À 2 to NO, so HSA-heme-Fe(II) nitrosylation does not occur [25] .
Values of the pseudo-first-order rate constant for the NO [21, 28, 30, 31] according to the minimum reaction mechanism depicted in Scheme 1 [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] , where the second process corresponds to the very fast nitrosylation of HSA-heme-Fe(II) in the presence of sodium dithionite [8] .
Values of k were determined using the following equation [21, 28, 30, 31] :
Values of the second-order rate constant for the NO 
Obviously, the value of k on refers to the interaction of NO À 2 with HSA-heme-Fe(II) under the general assumption that this process represents the rate-limiting step in the overall reaction reported in Scheme 1, as supported by previous observations [21, 28, 30, 31] .
Values of the dissociation equilibrium constant for the binding of warfarin to HSA-heme-Fe(II) (i.e., H) were determined from the dependence of k on on the drug concentration (i.e., [warfarin] ), according to the following equation [8] :
where k on(0) indicates the value of k on obtained in the absence of warfarin.
The results are given as the mean values of at least four experiments plus or minus the corresponding standard deviation. All data were analyzed using the Matlab program (The Math Works Inc., Natick, MA, USA).
Results and discussion
In the absence of NO [6, 8] ), differences in the absorption spectra of HSA-heme-Fe(II) and HSA-heme-Fe(II)-NO in the absence and presence of warfarin reflect the binding of the drug to the ferrous heme protein derivatives. These spectroscopic observations agree with previous data [3, 6, 8, 32, 33] indicating that the heme Fe(II) atoms of HSA-heme-Fe(II) and of HSA-hemeFe(II)-NO are predominantly tetra-and penta-coordinate, respectively. In contrast, warfarin binding induces the formation of the proximal axial ligand of the heme Fe(II) atom, which is predominantly penta-and hexa-coordinate in drug-bound HSA-heme-Fe(II) and HSA-heme-Fe(II)-NO, respectively. Lastly, the optical absorption spectra of HSA-heme-Fe(II) and HSA-heme-Fe(II)-NO are essentially independent of the allosteric effector [3, 6, 8, 15, [32] [33] [34] [35] .
Under all the experimental conditions, the time course of the NO À 2 -mediated conversion of HSA-heme-Fe(II) to HSA-heme-Fe(II)-NO corresponds to a monomolecular process for more than 80 % of its course (Fig. 1A) . Values of the pseudo-first-order rate constant for the NO À 2 -mediated conversion of (warfarin-)HSA-heme-Fe(II) to (warfarin-) HSA-heme-Fe(II)-NO (i.e., k; see Eq. 1) are wavelength independent at fixed NO À 2 and warfarin concentrations (data not shown). According to the literature [25] , values of k are independent of the dithionite concentration between 1.0 9 10 -3 and 5.0 9 10 -3 M (data not shown). Values of k increase linearly with the NO À 2 concentration in the absence and presence of warfarin (Fig. 1, panel  B) . Analysis of the data reported in Fig. 1 (panel B) according to Eq. 2 allowed the determination of values of the second-order rate constant for the NO À 2 -mediated conversion of HSA-heme-Fe(II) to HSA-heme-Fe(II)-NO (i.e., k on ; corresponding to the slope of the linear plot). The y intercept of the linear plot corresponds to zero, indicating that NO À 2 -mediated conversion of HSA-hemeFe(II) to HSA-heme-Fe(II)-NO can be considered an irreversible process. Values of the rate constants for the NO À 2 -mediated conversion of HSA-heme-Fe(II) to HSAheme-Fe(II)-NO are lower by several orders of magnitude than those of (warfarin-)HSA-heme-Fe(II) nitrosylation [8] . This indicates that the formation of the transient HSAheme-Fe(III) species (see Scheme 1), which is quickly converted to HSA-heme-Fe(II) by reaction with dithionite, represents the rate-limiting step of the NO À 2 -mediated conversion of HSA-heme-Fe(II) to HSA-heme-Fe(II)-NO. This statement finds support from the observation that the reductive nitrosylation of HSA-heme-Fe(III) by NO does indeed exhibit a much faster rate constant [13] . In addition, it must be recalled that, in the absence of warfarin, a significant fraction of the HSA-heme-Fe(II) is tetra-coordinate (lacking the two axial ligands), being in fast equilibrium with the penta-coordinate form. However, the addition of warfarin brings about the disappearance of the tetra-coordinate species in favor of penta-and hexa-coordinate HSAheme-Fe(II) [10] . Therefore, the faster NO À 2 -mediated conversion of HSA-heme-Fe(II) to HSA-heme-Fe(III), which represents the rate-limiting step of the whole reaction, in the absence of warfarin might reflect a faster NO À 2 -mediated oxidation process for the tetra-coordinate fraction of HSAheme-Fe(II).
As reported for most heme proteins [21-28, 30, 31] , the NO (Fig. 2) . The values of the slopes of the linear fits of plots of logk on versus pH are -0.99 ± 0.05 and -1.04 ± 0.05 in the absence and presence of 1.0 9 10 -3 M warfarin, respectively. In contrast with all the penta-and hexa-coordinate heme proteins investigated [21-28, 30, 31] , values of k on for the nitrite reductase activity of human cytoglobin do not increase by one order of magnitude on increasing the proton concentration by one pH unit. Indeed, values of k on for the nitrite reductase activity of human cytoglobin are essentially independent of pH between 8.5 and 7.0 (the average value being *0.14 M -1 s -1
), and increase from 0.7 to 2.1 M -1 s -1 on lowering the pH from 6.5 to 5.5. This behavior has been interpreted by taking into account the reversible pH-dependent penta-to hexa-coordinate transition of the heme Fe(II) atom [29] . Table 1 ) [8, 10] . The higher affinity of warfarin for HSA-heme-Fe(II)-NO than for HSAheme-Fe(II)-CO may reflect the different coordination states of the ligand-bound heme Fe(II) atom, which are pentacoordinate in HSA-heme-Fe(II)-NO and hexa-coordinate in HSA-heme-Fe(II)-CO (see Table 1 ) [8, 10, [32] [33] [34] [35] . Lastly, the higher affinity of warfarin for HSA than for the HSAheme-Fe(II) and HSA-heme-Fe(III) derivatives reflects the heme-Fe-based inhibition of drug binding to HSA-heme-Fe (see Table 1 ) [1] [2] [3] 32] . To this end, it should be noted that, in most cases, the binding of warfarin to the primary FA7 site affects ligand (i.e., heme Fe) binding to the FA1 site allosterically, but it does not induce any relevant alteration in the absorbance spectroscopic properties of HSA-heme-Fe in the Soret region or of the heme-Fe-based reactivity. Indeed, these effects occur at warfarin concentrations [10 -5 M, thus accounting for a second binding site that has been assigned to FA2 [8] . Warfarin binding to the secondary FA2 site (1) drives the conformational transition(s) of HSA from the N (native) form toward the B (basic) form observed in the presence of FA, affecting the neighboring FA1 cleft (Fig. 4 ) [2, 3] , and (2) induces a distortion of the heme Fe atom ligand field which is compatible with the increase in the coordination number from 4 to 5 and from 5 to 6 for HSA-heme-Fe(II) and HSA-heme-Fe(II)-NO, respectively. Changes in the coordination numbers of HSA-heme-Fe(II) and HSAheme-Fe(II)-NO upon ligand binding have been interpreted via comparative analysis of their absorbance, EPR, and Raman spectroscopic properties as well as of the heme Fe reactivity of globins that are considered molecular models [8, [32] [33] [34] [35] .
The comparative analysis of k on values for the NO À 2 -mediated conversion of ferrous deoxygenated heme proteins to their ferrous nitrosylated derivatives (see Table 2 ) allows the following considerations. Values of k on for the [30] . Moreover, the low k on values for the NO À 2 -mediated conversion of ferrous human cytoglobin to the ferrous nitrosylated derivative could reflect the hexacoordination of the heme-Fe(II) atom [29] . Furthermore, the NO À 2 -mediated conversion of ferrous human neuroglobin to the ferrous nitrosylated derivative range between 1.2 9 10 -2 and 1.2 9 10 -1 M -1 s -1 , reflecting the reversible redox-linked hexa-to penta-coordinate transition of the heme Fe(II) atom. In fact, under oxidative conditions, the formation of the Cys46-Cys55 bridge stabilizes the highly reactive penta-coordinate heme Fe(II) atom facilitating the reaction. In contrast, under reductive conditions, the cleavage of the Cys46-Cys55 bridge leads to the formation of the low-reactivity hexa-coordinate heme Fe(II) atom. Accordingly, the Cys46Ala and Cys55Ala mutations, which stabilize the hexa-coordinate heme Fe(II) atom, slow down the NO À 2 -mediated conversion of ferrous human neuroglobin to its ferrous nitrosylated derivative. Also, the HisE7Leu and HisE7Gln mutations, which lead to a stable penta-coordinate heme Fe(II) atom, facilitate the nitrite reductase activity of ferrous human neuroglobin [30] . However, although the heme Fe atoms of Synechocystis hemoglobin, A. thaliana nonsymbiotic hemoglobins classes 1 and 2, and rice nonsymbiotic hemoglobin class 1 have been reported to be basically hexa-coordinate, k on values for the NO . This finding has been interpreted assuming that a substantial fraction of the ferrous derivative of these proteins display a penta-coordinate heme geometry (see [28, 31] ). Lastly, the NO À 2 -mediated conversion of HSAheme-Fe(II) and ferrous human hemoglobin to their ferrous nitrosylated derivatives is impaired allosterically (present study and [22, 23] ).
Since the nitrite reductase activity of HSA-heme-Fe(II) is potentially of interest in the in vivo situation, the following implications can be argued from the present results:
1. The nitrite reductase activity of HSA-heme-Fe(II) in the bloodstream may play a role in acidosis and near anoxia (which occurs in ischemic conditions); in fact, the rate of NO generation increases linearly upon lowering the pH and with the NO À 2 concentration under anaerobic conditions (present study). 2. The conversion of NO À 2 to NO, as catalyzed by HSAheme-Fe(II), may occur not only in healthy subjects but also-especially-in patients affected by severe hematologic diseases characterized by excessive intravascular hemolysis. In fact, the HSA-heme-Fe plasmatic level increases from ca. 1 9 10 -6 M in healthy subjects to ca. 4 9 10 -5 M in patients, with HSA acting as the main heme Fe plasma scavenger (see [3] ). 3. Drugs modulate both the binding of heme Fe to HSA and the HSA-heme-Fe reactivity; accordingly, the [28] b pH 7.4 and 25°C. From [31] c pH 7.4 and 25°C. From [30] d pH 7.4 and 25°C. From [22] e pH 7.4 and 25°C. From [30] f pH 7.4 and 25°C. From [26] g pH 7.0 and 25°C. From [29] h pH 7.4 and 25°C. From [30] . In human neuroglobin Cys46-Cys55, the Cys46 and Cys55 residues form an intramolecular disulfide bond i pH 7.4 and 25°C. From [30] . In human neuroglobin Cys46/Cys55, the Cys46 and Cys55 residues do not form an intramolecular disulfide bond j pH 7.4 and 20°C (present study) k pH 7.4 and 25°C. From [29] binding of heme Fe to HSA affects drug release, possibly inducing adverse effects. 4. The binding of warfarin to the primary FA7 site of HSA allosterically inhibits the binding of heme Fe(III) to the FA1 site and vice versa. Values of the dissociation equilibrium constants for the binding of warfarin to HSA and HSA-heme-Fe(III) are *3 9 10 -6 and *3 9 10 -5 M, respectively. Accordingly, values of the dissociation equilibrium constants for the binding of heme Fe(III) to HSA and warfarin-HSA are *1 9 10 -8 and *1 9 10 -7 M, respectively. On the other hand, the binding of warfarin to the secondary FA2 site of HSA-heme-Fe(II) modulates the heme-Fe(II)-based reactivity and vice versa [3, 6, 8, 10, 32] . Values of the dissociation equilibrium constants for the binding of warfarin to HSA-hemeFe(II) range between 2.6 9 10 -4 and 4.5 9 10 -4 M (see Table 1 ). Accordingly, values of the dissociation equilibrium constants for the binding of warfarin to HSA-heme-Fe(II)-NO and HSA-heme-Fe(II)-CO are 6.2 9 10 -5 and 7.4 9 10 -4 M, respectively (see Table 1 ). Considering the values of the dissociation equilibrium constants for the binding of warfarin to HSA, HSA-heme-Fe(III), and HSA-heme-Fe(II) derivatives (see [3, 6, 8, 10, 32] , the present study, and Table 1) , and the plasma level of warfarin (1.4 9 10 -5 M) [39] , the molar fraction of the drug bound to the FA7 site of HSA and HSA-heme-Fe(III) is [40 %, whereas the molar fraction of warfarin bound to the FA2 site of HSA-heme-Fe(II) is negligible. Therefore, warfarin may affect the binding of heme Fe to HSA but not the reactivity of HSAheme-Fe(II) in vivo. 5. The modulation of the functions of HSA (-heme-Fe) by drugs strongly supports the view that HSA not only acts as a heme carrier but also may display heme-Febased reactivity that is competitively inhibited and/or modulated by allosteric effectors (see [1] [2] [3] and the present study).
